197 related articles for article (PubMed ID: 32515546)
21. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
22. The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment.
Huang P; Xu X; Wang L; Zhu B; Wang X; Xia J
J Cell Mol Med; 2014 Feb; 18(2):218-30. PubMed ID: 24268047
[TBL] [Abstract][Full Text] [Related]
23. Trophoblast subtype-specific EGFR/ERBB4 expression correlates with cell cycle progression and hyperplasia in complete hydatidiform moles.
Fock V; Plessl K; Fuchs R; Dekan S; Milla SK; Haider S; Fiala C; Knöfler M; Pollheimer J
Hum Reprod; 2015 Apr; 30(4):789-99. PubMed ID: 25740878
[TBL] [Abstract][Full Text] [Related]
24. β-Heregulin impairs EGF induced PLC-γ1 signalling in human breast cancer cells.
Rommerswinkel N; Keil S; Adawy A; Hengstler JG; Niggemann B; Zänker KS; Dittmar T
Cell Signal; 2018 Dec; 52():23-34. PubMed ID: 30165102
[TBL] [Abstract][Full Text] [Related]
25. The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4.
Riese DJ; Kim ED; Elenius K; Buckley S; Klagsbrun M; Plowman GD; Stern DF
J Biol Chem; 1996 Aug; 271(33):20047-52. PubMed ID: 8702723
[TBL] [Abstract][Full Text] [Related]
26. Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3.
Young CD; Nolte EC; Lewis A; Serkova NJ; Anderson SM
Breast Cancer Res; 2008; 10(4):R70. PubMed ID: 18700973
[TBL] [Abstract][Full Text] [Related]
27. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
28. Growth factor-dependent ErbB vesicular dynamics couple receptor signaling to spatially and functionally distinct Erk pools.
Brüggemann Y; Karajannis LS; Stanoev A; Stallaert W; Bastiaens PIH
Sci Signal; 2021 May; 14(683):. PubMed ID: 34006609
[TBL] [Abstract][Full Text] [Related]
29. Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3.
Sak MM; Szymanska M; Bertelsen V; Hasmann M; Madshus IH; Stang E
Carcinogenesis; 2013 Sep; 34(9):2031-8. PubMed ID: 23698633
[TBL] [Abstract][Full Text] [Related]
30. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.
Contessa JN; Abell A; Mikkelsen RB; Valerie K; Schmidt-Ullrich RK
Breast Cancer Res Treat; 2006 Jan; 95(1):17-27. PubMed ID: 16267617
[TBL] [Abstract][Full Text] [Related]
31. ErbB kinases and NDF signaling in human prostate cancer cells.
Grasso AW; Wen D; Miller CM; Rhim JS; Pretlow TG; Kung HJ
Oncogene; 1997 Nov; 15(22):2705-16. PubMed ID: 9400997
[TBL] [Abstract][Full Text] [Related]
32. Neuregulin/erythroblastic leukemia viral oncogene homolog 3 autocrine loop contributes to invasion and early recurrence of human hepatoma.
Hsieh SY; He JR; Hsu CY; Chen WJ; Bera R; Lin KY; Shih TC; Yu MC; Lin YJ; Chang CJ; Weng WH; Huang SF
Hepatology; 2011 Feb; 53(2):504-16. PubMed ID: 21246584
[TBL] [Abstract][Full Text] [Related]
33. The emergence of ErbB2 expression in cultured rat hepatocytes correlates with enhanced and diversified EGF-mediated signaling.
Scheving LA; Zhang L; Stevenson MC; Kwak ES; Russell WE
Am J Physiol Gastrointest Liver Physiol; 2006 Jul; 291(1):G16-25. PubMed ID: 16769812
[TBL] [Abstract][Full Text] [Related]
34. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.
Xia W; Liu LH; Ho P; Spector NL
Oncogene; 2004 Jan; 23(3):646-53. PubMed ID: 14737100
[TBL] [Abstract][Full Text] [Related]
35. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.
Lewis GD; Lofgren JA; McMurtrey AE; Nuijens A; Fendly BM; Bauer KD; Sliwkowski MX
Cancer Res; 1996 Mar; 56(6):1457-65. PubMed ID: 8640840
[TBL] [Abstract][Full Text] [Related]
36. ErbB receptors mediate both migratory and proliferative activities in human melanocytes and melanoma cells.
Gordon-Thomson C; Jones J; Mason RS; Moore GP
Melanoma Res; 2005 Feb; 15(1):21-8. PubMed ID: 15714117
[TBL] [Abstract][Full Text] [Related]
37. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B
Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604
[TBL] [Abstract][Full Text] [Related]
38. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
Ram TG; Hosick HL; Ethier SP
J Cell Physiol; 2000 Jun; 183(3):301-13. PubMed ID: 10797304
[TBL] [Abstract][Full Text] [Related]
39. Heregulin-ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells.
Yarar D; Lahdenranta J; Kubasek W; Nielsen UB; MacBeath G
Mol Cancer Ther; 2015 Sep; 14(9):2072-80. PubMed ID: 26116360
[TBL] [Abstract][Full Text] [Related]
40. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
